Nextech V Oncology S.C.S. SICAV-SIF 13D and 13G filings for PMV Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-14 4:00 pm Sale |
2021-12-31 | 13G | PMV Pharmaceuticals, Inc. PMVP |
Nextech V Oncology S.C.S. SICAV-SIF | 1,385,807 3.100% |
-1,142,483 (-45.19%) |
Filing |
| 2021-02-16 4:00 pm Purchase |
2020-12-31 | 13G | PMV Pharmaceuticals, Inc. PMVP |
Nextech V Oncology S.C.S. SICAV-SIF | 2,528,290 5.600% |
2,528,290 (New Position) |
Filing |